Biostatistic/Outcomes Cores

异基因造血干细胞移植（HSCT）是许多患者的唯一治愈性疗法， 血液恶性肿瘤和骨髓衰竭。成功完成HSCT的关键障碍是 移植物抗宿主病（GVHD）。本次更新研究项目的最终目标是 应用是为了进一步提高我们对aGVHD和cGVHD的病理生理学的理解， 通过靶向不同的细胞群体，开发预防和治疗cGVHD的新策略 在这两种综合征中，同时保持GVL。实现这一目标的关键，从而导致 该计划项目的成功是与3个领域中的每个人进行动态生物统计合作。 项目和其他三个核心。 生物统计核心C的目的是提供以下服务，这些服务将由 研究项目包括在这个项目中。 1.为转化临床研究提供生物统计学合作。 2.为转化动物研究提供生物统计学合作。 3.为转化实验室研究提供生物统计学和/或生物信息学合作。 4.为转化研究提供研究基础设施。 5.为数据处理、统计分析、标准化报告和 质量控制 相关性（参见说明）： 预防或治疗cGVHD，从而降低相关的发病率和死亡率是重要的，因为1） HSCT技术的改进允许使用老年供体和老年患者来接受移植， 因此，更多的患者接受HSCT，2）支持性治疗的改善导致更好的生存期， cGVHD发生的时间段。

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for many patients with hematologic malignancies and marrow failure. A critical hurdle in accomplishment of successful HSCT has been graft-versus-host disease (GVHD).The ultimate objective of the research projects in this renewal application is to further improve our understanding of the pathophysiology of aGVHD and cGVHD and to develop novel strategies for both prevention and therapy of cGVHD by targeting distinct cellular populations in these two syndromes while maintaining GVL. Key to achieve this objective and thus to lead to the success of this program project is dynamic biostatistical collaboration with individuals in each of the 3 projects and the 3 other Cores. The purpose of the Biostatistics Core C is to provide the following services that will be utilized by the research projects included in this Program Project. 1. To provide biostatistical collaboration for translational clinical research studies. 2. To provide biostatistical collaboration for translational animal research studies. 3. To provide biostatistical and/or bioinformatics collaboration for translational laboratory research studies. 4. To provide research infrastructure for translational research. 5. To provide computing resources for data processing, and statistical analysis, standardized reporting, and quality control. RELEVANCE (See instructions): Preventing or treating cGVHD, thus reducing related morbidity and mortality, is important because 1) improvements in HSCT technology allow the use of older donors and older patients to receive transplant, thus more patients undergo HSCT, and 2) improvements in supportive care result in better survival in later time periods when cGVHD occurs.